Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

References

• AbreyLEYahalomJDeAngelisLMTreatment for primary CNS lymphoma: the next stepJ Clin Oncol20001831445010963643
   PubMed Web of Science ®Google Scholar
• [ACS] American Cancer SocietyCancer facts and figures 2006 [online]2006 Accessed on 28 December 2006. URL: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
   Google Scholar
• BerneisKKoflerMBollagWThe degradation of DNA by a new tumor inhibiting compoundExperientia196319132313971061
   PubMedGoogle Scholar
• BollagWGrunbergEThe degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxideExperientia196319130113968615
   PubMedGoogle Scholar
• BrandesAAErmaniMTurazziSProcarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II studyJ Clin Oncol1999176455010080610
   PubMed Web of Science ®Google Scholar
• BrandesAATosoniAVastolaFEfficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II studyCancer200410120798515372474
   PubMed Web of Science ®Google Scholar
• BrunnerKWYoungCWA methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51 patientsAnn Intern Med196563698614305970
   PubMedGoogle Scholar
• BucknerJCGesmeDJrO’FallonJRPhase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalitiesJ Clin Oncol200321251512525516
   PubMed Web of Science ®Google Scholar
• CanellosGPAndersonJRPropertKJChemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, MOPP alternating with ABVDN Engl J Med19923271478841383821
   PubMed Web of Science ®Google Scholar
• CatenoixHHonnoratJCartalat-CarelS[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents.]Rev Neurol200616210697517086143
   PubMedGoogle Scholar
• ChaarBTSalemPPetruskaPJProcarbazine for non-Hodgkin’s lymphomaLeukemia Lymphoma2006476374016690522
   PubMed Web of Science ®Google Scholar
• ChryssanthouCPWallachRCAtchisonMMeiotic chromosomal changes and sterility produced by nitrogen mustard and procarbazine in miceFertil Steril198339971026848396
   PubMed Web of Science ®Google Scholar
• CornBWMarcusSMTophamAWill primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?Cancer1997792409139191531
   PubMed Web of Science ®Google Scholar
• CoyleTBaptistaJWinfieldJMechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II studyJ Clin Oncol199082014182230893
   PubMed Web of Science ®Google Scholar
• DeAngelisLMDelattreJYPosnerJBRadiation-induced dementia in patients cured of brain metastasesNeurology198939789962725874
   PubMed Web of Science ®Google Scholar
• DeVitaVTJrCanellosGPChabnerBAdvanced diffuse histiocytic lymphoma, a potentially curable diseaseLancet197512485046388
   PubMed Web of Science ®Google Scholar
• DevitaVTJrSerpickAACarbonePPCombination chemotherapy in the treatment of advanced Hodgkin’s diseaseAnn Intern Med197073881955525541
   PubMed Web of Science ®Google Scholar
• DiehlVFranklinJPfreundschuhMStandard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s diseaseN Engl J Med200334823869512802024
   PubMed Web of Science ®Google Scholar
• DufourCGrillJLellouch-TubianaAHigh-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocolEur J Cancer20064229394516962317
   PubMed Web of Science ®Google Scholar
• DugganDBPetroniGRJohnsonJLRandomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an Intergroup trialJ Clin Oncol2003216071412586796
   PubMed Web of Science ®Google Scholar
• EngelCLoefflerMSchmitzHAcute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group (GHSG)Ann Oncol20001111051411061603
   PubMed Web of Science ®Google Scholar
• EriksonJMTweedieDJDucoreJMCytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cellsCancer Res198949127332908840
   PubMed Web of Science ®Google Scholar
• EzdinliEZAndersonJRMelvinFModerate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphomaJ Clin Oncol19853769753839262
   PubMed Web of Science ®Google Scholar
• FermeCMounierNCasasnovasOLong-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA)Blood200610746364216478882
   PubMed Web of Science ®Google Scholar
• FriedmanHSChabnerBALongoDLAlkylating agents in cancer chemotherapy and biotherapy20014th editionPhiladelphiaLippincott Williams & Wilkins415
   Google Scholar
• FriedmanHSJohnsonSPDongQMethylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograftCancer Res199757293369230204
   PubMed Web of Science ®Google Scholar
• GlaserSLJarrettRFThe epidemiology of Hodgkin’s diseaseBaillieres Clin Haematol1996940168922237
   PubMed Web of Science ®Google Scholar
• GobbiPGBrogliaCLevisAMOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10-year results, late toxicity, and second tumorsClin Cancer Res2006125293516428496
   PubMedGoogle Scholar
• GobbiPGLevisAChisesiTABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiJ Clin Oncol200523919820716172458
   PubMed Web of Science ®Google Scholar
• GrossmanSACarsonKABatchelorTTThe effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideClin Cancer Res20061251748116951236
   PubMedGoogle Scholar
• HerrlingerUBruggerWBambergMPCV salvage chemotherapy for recurrent primary CNS lymphomaNeurology2000541707810762527
   PubMed Web of Science ®Google Scholar
• HildebrandJde WitteOSahmoudTResponse of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - a phase II studyJ Neurooncol199837155609524094
   PubMedGoogle Scholar
• Hoang-XuanKTaillandierLChinotOChemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor GroupJ Clin Oncol20032127263112860951
   PubMed Web of Science ®Google Scholar
• JeremicBJovanovicDDjuricLJAdvantage of post-radiotherapy chemotherapy with CCNU, procarbazine and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomasJ Chemother1992412361321239
   PubMed Web of Science ®Google Scholar
• KappelleACPostmaTJTaphoornMJPCV chemotherapy for recurrent glioblastoma multiformeNeurol20015611820
   PubMed Web of Science ®Google Scholar
• KellyKMHutchinsonRJSpostoRFeasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: preliminary results from the Children’s Cancer Group Study CCG-59704Ann Oncol200213Suppl 11071112078889
   PubMedGoogle Scholar
• KenisYDe SmedtJTagnonHJThe action of Natulan in 94 cases of solid tumorsEur J Cancer196625175962294
   PubMedGoogle Scholar
• KimLHochbergFHThorntonAFProcarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomasJ Neurosur1996856027
   PubMed Web of Science ®Google Scholar
• KyritsisAPYungWKJaeckleKACombination of 6-thioguanine, procarbazine, lomustine and hydroxyurea for patients with recurrent malignant gliomasNeurosurgery19963992168905746
   PubMed Web of Science ®Google Scholar
• LevinVALambornKWaraWPhase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine and vincristine chemotherapy with radiotherapy for treating malignant glioma in childrenNeuro-oncol2000222811302250
   PubMed Web of Science ®Google Scholar
• LevinVASilverPHanniganJSuperiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas. NCOG 6G61 final reportInt J Radiat Oncol Biol Phys19901832142154418
   PubMed Web of Science ®Google Scholar
• LevinVAUhmJHJaeckleKAPhase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiformeClin Cancer Res2000638788411051233
   PubMed Web of Science ®Google Scholar
• LevinVAWaraWMDavisRLPhase III comparison of BCNU and the combination of procarbazine, CCNU and vincristine administered after radiotherapy with hydroxyurea for malignant gliomasJ Neurosurg198563218232991486
   PubMed Web of Science ®Google Scholar
• LivingstonRBCarterSKSingle agents in cancer chemotherapy1970New YorkIFI/Plenum Data Corp.31836
   Google Scholar
• LoefflerMHasencleverDDiehlVModel based development of the BEACOPP regimen for advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study GroupAnn Oncol19989738
   PubMedGoogle Scholar
• LongoDLYoungRCHubbardSMProlonged initial remission in patients with nodular mixed lymphomaAnn Intern Med198410065166370065
   PubMed Web of Science ®Google Scholar
• LowenbraunSDeVitaVTSerpickAACombination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcomaCancer1970251018254910254
   PubMedGoogle Scholar
• LuceJKGambleJFWilsonHECombined cyclophosphamide vincristine, and prednisone therapy of malignant lymphomaCancer197128306174935774
   PubMed Web of Science ®Google Scholar
• McAllisterLDDoolittleNDGuastadisegniPECognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphomaNeurosurgery200046516110626935
   PubMed Web of Science ®Google Scholar
• MalekFAMoritzKUFanghanelJEffects of prenatal procarbazine administration on intrauterine development in ratsAnn Anat20031851171912725435
   PubMedGoogle Scholar
• MartinHSchubertJCCytostatic treatment of polycythemia vera with a methylbenzylhydrazine derivativeDtsch Med Wochenschr1966915575900941
   PubMedGoogle Scholar
• MassoudMArmandJPRibragVProcarbazine in haematology: an old drug with a new life?Eur J Cancer2004401924715315798
   PubMed Web of Science ®Google Scholar
• MontotoSCamosMLopez-GuillermoAHybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin diseaseCancer2000882142810813727
   PubMedGoogle Scholar
• [MRC] Medical Research Council Brain Tumor Working PartyRandomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trialJ Clin Oncol2001195091811208845
   PubMed Web of Science ®Google Scholar
• NewellDGescherAHarlandSN-methyl antitumor agents: a distinct class of anticancer drugs?Cancer Chemother Pharmacol198719911023552281
   PubMed Web of Science ®Google Scholar
• NewlandsESFosterTZaknoenSPhase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomasBr J Cancer2003892485112865911
   PubMed Web of Science ®Google Scholar
• NewtonHBJunckLBrombergJProcarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failureNeurol19904017436
   PubMed Web of Science ®Google Scholar
• NgAKBernardoMVWellerESecond malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood200210019899612200357
   PubMed Web of Science ®Google Scholar
• NicholsonWMBeardMECrowtherDCombination chemotherapy in generalized Hodgkin’s diseaseBr Med J197037105427500
   PubMedGoogle Scholar
• NiitsuNUmedaMBiweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins’s lymphomaLeukemia1998121457609737696
   PubMedGoogle Scholar
• PazdurRCoiaLRHoskinsWJCancer management: a multidisciplinary approach2003New YorkThe Oncology Group
   Google Scholar
• PeggAEMammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agentsCancer Res1990506119292205376
   PubMed Web of Science ®Google Scholar
• PradosMDScottCCurranWJJrProcarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapyJ Clin Oncol19991733899510550132
   PubMed Web of Science ®Google Scholar
• PreissRBaumannFRegenthalRPlasma kinetics of procarbazine and azo-procarbazine in humansAnti-Cancer Drugs200617758016317293
   PubMedGoogle Scholar
• RodriguezLAPradosMSilverPReevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumorsCancer198964242032555038
   PubMed Web of Science ®Google Scholar
• RüfferJUBallovaVGlossmannJBEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease— results of the German Hodgkin Study GroupLeuk Lymphoma2005461561716236610
   PubMed Web of Science ®Google Scholar
• RutinshauserABollagWCytological investigations of a new class of cytotoxic agents methylhydrazine derivativesExperientia196319131213975694
   PubMedGoogle Scholar
• Sandberg-WollheimMMalmstromPStrombladLA randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4Cancer1991682292049748
   PubMed Web of Science ®Google Scholar
• SertoliMRSantiniGChisesiTMACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study GroupJ Clin Oncol1994121366747517442
   PubMed Web of Science ®Google Scholar
• ShpilbergOShiffJChetritAThe cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin’s lymphoma. Long term follow-up in 51 patientsCancer1994743029337525042
   PubMedGoogle Scholar
• StegeEMKrosJMde BruinHGSuccessful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristineCancer2005103802915637687
   PubMed Web of Science ®Google Scholar
• SupkoJGHeXWhitneyCPharmacokinetics of procarbazine and metabolites involved in its bioactivation in patients with recurrent anaplastic astrocytoma [abstract]Proc Am Soc Clin Oncol2002212086
   Google Scholar
• TakenakaTMikuniCMiuraAAlternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin’s disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology GroupJpn J Clin Oncol2000301465210798542
   PubMed Web of Science ®Google Scholar
• van den BentMJDelattreJ-YBrandesAAFirst analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendrogliomaJ Clin Oncol2005231503
   Google Scholar
• van den BentMJCarpentierAFBrandesAAAdjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialJ Clin Oncol20062427152216782911
   PubMed Web of Science ®Google Scholar
• YungWKAlbrightREOlsonJA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer2000835889310944597
   PubMed Web of Science ®Google Scholar
• ZbindenGUnscheduled DNA synthesis in the testis, a secondary test for the evaluation of chemical mutagensArch Toxicol198046139497235990
   PubMedGoogle Scholar
• ZellerPGutmannHHegedusBMethylhydrazine derivatives, a new class of cytotoxic agentsExperientia19631912914003433
   PubMedGoogle Scholar